OncoMatch

OncoMatch/Clinical Trials/NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Is NCT07090499 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PF-08046876 for advanced/metastatic solid tumors.

Phase 1RecruitingPfizerNCT07090499Data as of May 2026

Treatment: PF-08046876 — The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Urothelial Carcinoma

Non-Small Cell Lung Carcinoma

Small Cell Lung Cancer

Head and Neck Squamous Cell Carcinoma

Esophageal Carcinoma

Gastric Cancer

Pancreatic Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 2 prior lines

Must have received: standard treatments — advanced

progression or relapse following standard treatments

Cannot have received: antibody-drug conjugate (sacituzumab govitecan, trastuzumab deruxtecan)

Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope National Medical Center · Duarte, California
  • City of Hope at Irvine Lennar · Irvine, California
  • Ronald Reagan UCLA Medical Center · Los Angeles, California
  • UCLA Department of Medicine-Hematology/Oncology · Los Angeles, California
  • Santa Monica UCLA Medical Center & Orthopaedic Hospital · Santa Monica, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify